Michael Banks, MD, discusses the new genomic test created to determine a patient's tumor mutation burden, which could help identify patients that would benefit from immunotherapy.
Larry Smarr, Founding Director, CALIT2, details the growing epidemic of children, especially those with gastrointestinal disorders, who were not exposed to the necessary microbiomes during the formative...
